Trial reportRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2017
Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.
Trial report in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Proton Radiation Therapy: A Systematic Review of Treatment-Related Side Effects and Toxicities.International journal of molecular sciences · 2024Pooled it
- Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer.Radiation oncology (London, England) · 2018Trial
- Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.Journal of radiation research · 2026Article
- Carbon ion radiotherapy and radiation-induced lung injury: clinical evidence, mechanistic insights, and future directions.Frontiers in oncology · 2026Review
- Stereotactic ablative body radiation therapy for treatment of ultra-central lung tumors: a narrative review.Journal of thoracic disease · 2025Review
- Investigating the potential of proton therapy for hypoxia-targeted dose escalation in non-small cell lung cancer.Radiation oncology (London, England) · 2021Article
- Dosimetry, Efficacy, Safety, and Cost-Effectiveness of Proton Therapy for Non-Small Cell Lung Cancer.Cancers · 2021Review
- Modelling and measurements of distributions in an adult human phantom undergoing proton scanning beam radiotherapy: lung- and prostate-located tumours.Radiation and environmental biophysics · 2021Article
- Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations.Journal of thoracic disease · 2021Review
- Research progress on radiotherapy technology and dose fraction scheme for advanced gliomas.Translational cancer research · 2020Review
- End-of-Range Radiobiological Effect on Rib Fractures in Patients Receiving Proton Therapy for Breast Cancer.International journal of radiation oncology, biology, physics · 2020Article
- Online adaptive dose restoration in intensity modulated proton therapy of lung cancer to account for inter-fractional density changes.Physics and imaging in radiation oncology · 2020Article
- Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer.Lung Cancer (Auckland, N.Z.) · 2020Article
- Proton therapy for non-small cell lung cancer: the road ahead.Translational lung cancer research · 2019Review
- Proton beam therapy for cancer in the era of precision medicine.Journal of hematology & oncology · 2018Review
- Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702).Japanese journal of clinical oncology · 2018Article
- Proton Therapy in Non-small Cell Lung Cancer.Current treatment options in oncology · 2018Review
- Four-dimensional Plan Optimization for the Treatment of Lung Tumors Using Pencil-beam Scanning Proton Radiotherapy.Cureus · 2018Article
- Reirradiation for locoregionally recurrent non-small cell lung cancer.Journal of thoracic disease · 2018Review
- [Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeThe aim of this phase I/II study was to assess the long-term clinical benefits and toxicities of proton beam therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). PATIENTS AND
methodsFrom June 2006 to September 2011, 35 patients with medically inoperable T1N0M0 (central or superior location, 12 patients) or T2-3N0M0 (any location, 23 patients) NSCLC were treated with 87.5Gy at 2.5Gy/fraction of proton therapy. Toxicities were scored according to the Common Terminology Criteria for Adverse Events, version 4.0.
resultsThe median follow-up time was 83.1months (95% CI: 69.2-97.1months). For all 35 patients, the 1, 3, and 5-year overall survival rates were 85.7%, 42.9%, and 28.1%, respectively. The 5-year local recurrence-free, regional recurrence-free, and distant metastasis-free survival rates were 85.0%, 89.2%, and 54.4%, respectively. Different T stages had no effect on local and regional recurrence (p=0.499, p=1.00). However, with the increase in T stages, the distant metastasis rate increased significantly (p=0.006). The most common adverse effects were dermatitis (grade 2, 51.4%; grade 3, 2.9%) and radiation pneumonitis (grade 2, 11.4%; grade 3, 2.9%). Other grade 2 toxicities included esophagitis (2.9%), rib fracture (2.9%), heart toxicities (5.7%), and chest wall pain (2.9%).
conclusionsAccording to our long-term follow-up data, proton therapy with ablative doses is well tolerated and effective in medically inoperable early-stage NSCLC. Systemic therapy should be considered to reduce the rate of distant metastasis in cases of T2 and T3 lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.